Implantable cardioverter-defibrillators in the elderly: Rationale and specific age-related considerations

Europace

Volumn 17, Issue 2, 2014, Pages 174-186

  Barra, Sergio ^a   Providência, Rui ^b   Paiva, Luis ^c   Heck, Patrick ^a   Agarwal, Sharad ^a  

^a PAPWORTH HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

Author keywords

Arrhythmia; Clinical effectiveness; Cost effectiveness; Elderly; Implantable cardioverter defibrillator; Risk stratification; Safety; Sudden death; Survival

Indexed keywords

AGED; CARDIOVASCULAR MORTALITY; CLINICAL EFFECTIVENESS; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; HEART VENTRICLE ARRHYTHMIA; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; OVERALL SURVIVAL; PATIENT SAFETY; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; SUDDEN CARDIAC DEATH; SURVIVAL; VERY ELDERLY; ARRHYTHMIAS, CARDIAC; CARDIAC RESYNCHRONIZATION THERAPY; COST BENEFIT ANALYSIS; DEATH, SUDDEN, CARDIAC; PATIENT SELECTION; PROCEDURES; RISK ASSESSMENT; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ARRHYTHMIAS, CARDIAC; CARDIAC RESYNCHRONIZATION THERAPY; COST-BENEFIT ANALYSIS; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; HUMANS; PATIENT SELECTION; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84922463864     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euu296     Document Type: Review

References (93)

1. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83.
2. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352:225-37.
3. The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators.Acomparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337: 1576-83.
4. Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS et al.Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000;101:1297-302.
5. Kuck KH, Cappato R, Siebels J, Rüppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation 2000;102:748-54.
6. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter automatic defibrillator implantation trial investigators. N Engl J Med 1996;335:1933-40.
7. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter unsustained tachycardia trial investigators. N Engl J Med 1999; 341:1882-90
8. Epstein AE, Kay GN, Plumb VJ, McElderry HT, Doppalapudi H, Yamada T, et al. Implantable cardioverter-defibrillator prescription in the elderly. Heart Rhythm 2009;6:1136-43.
9. Ruskin JN, Camm AJ, Zipes DP, Hallstrom AP, McGrory-Usset ME. Implantable cardioverter defibrillator utilization based on discharge diagnoses from Medicare and managed care patients. J Cardiovasc Electrophysiol 2002;13:38-43.
10. Wiener JM, Tilly J. Population ageing in the United States of America: implications for public programmes. Int J Epidemiol 2002;31:776-81.
11. Anderson GF, Hussey PS. Population aging: a comparisonamong industrialized countries. Health Aff (Millwood) 2000;19:191-203.
12. Kong MH, Al-Khatib SM, Sanders GD, Hasselblad V, Peterson ED. Use of implantable cardioverter-defibrillators for primary prevention in older patients: a systematic literature review and meta-Analysis. Cardiol J 2011;18:503-14.
13. Huang DT, Sesselberg HW, McNitt S, Noyes K, Andrews ML, HallWJet al.MADIT-II Research Group. Improved survival associated with prophylactic implantable defibrillators in elderly patients with prior myocardial infarction and depressed ventricular function: a MADIT-II substudy. J Cardiovasc Electrophysiol 2007;18:833-8.
14. Chan PS, Nallamothu BK, Spertus JA, Masoudi FA, Bartone C, Kereiakes DJ, et al. Impact of age and medical comorbidity on the effectiveness of implantable cardioverter-defibrillators for primary prevention. Circ Cardiovasc Qual Outcomes 2009;2:16-24.
15. Earley A, Persson R, Garlitski AC, Balk EM, Uhlig K. Effectiveness of implantable cardioverter defibrillators for primary prevention of sudden cardiac death in subgroups a systematic review. Ann Intern Med 2014;160:111-21.
16. Boriani G, Ricci R, Toselli T, Ferrari R, Branzi A, Santini M. Implantable cardioverter defibrillators: from evidence of trials to clinical practice. Eur Heart J Suppl 2007;9: I66-73.
17. Santangeli P, Di Biase L, Dello RA, Casella M, Bartoletti S, Santarelli P, et al. Meta-Analysis: age and effectiveness of prophylactic implantable cardioverter defibrillators. Ann Intern Med 2010;153:592-9.
18. Healey JS, Hallstrom AP, Kuck KH, Nair G, Schron EP, Roberts RS, et al. Role of the implantable defibrillatoramong elderly patients with a history of life threatening ventricular arrhythmias. Eur Heart J 2007;28:1746-9.
19. Russo AM, Stainback RF, Bailey SR, Epstein AE, Heidenreich PA, JessupMet al.ACCF/ HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy: a report of the American College of Cardiology Foundation appropriate use criteria task force, Heart Rhythm Society, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. J AmColl Cardiol 2013;61:1318-68.
20. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, HatalaRet al.DINAMIT Investigators. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Eng J Med 2004;351:2481-8.
21. Bigger JT Jr. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmia after coronary-Artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigations. N Engl J Med 1966;335: 1933-40.
22. Hammill SC, Kremers MS, Kadish AH, Stevenson LW, Heidenreich PA, Lindsay BD, et al. Review of the ICD registry's third year, expansion to include lead data and pediatric ICD procedures, and role for measuring performance. Heart Rhythm 2009;6:1397-401.
23. Yung D, Birnie D, Dorian P, Healey JS, Simpson CS, Crystal E, et al. Survival after implantable cardioverter-defibrillator implantation in the elderly. Circulation 2013; 127:2383-92.
24. Proclemer A, Ghidina M, Gregori D, Facchin D, Rebellato L, Fioretti P, et al. Impact of the main implantable cardioverter-defibrillator trials in clinical practice: data from the Italian ICD Registry for the years 2005-07. Europace 2009;11:465-75.
25. Goonewardene M, Barra S, Heck P, Begley D, Fynn S, Virdee M, et al. Cardioverterdefibrillator implantation and generator replacement in the octogenarian. Europace, doi:10.1093/europace/euu248.
26. Krahn AD, Connolly SJ, Roberts RS, Gent M. ATMA Investigators. Diminishing proportional risk of sudden death with advancing age: implications for prevention of sudden death. Am Heart J 2004;147:837-40.
27. Grimm W, Stula A, Sharkova J, Alter P, Maisch B. Outcomes of elderly recipients of implantable cardioverter defibrillators. Pacing Clin Electrophysiol 2007;30:S134-8.
28. Ermis C, Zhu AX, Vanheel L, Sakaguchi RN, Lurie KG, Lu F, et al. Comparison of ventricular arrhythmia burden, therapeutic interventions, and survival, in patients , 75 and patients . or ' 75 years of age treated with implantable cardioverter defibrillators. Europace 2007;9:270-4.
29. Kadish A, Dyer A, Daubert JP, Quigg R, Estes NA, Anderson KP, et al. Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004;350:2151-8.
30. Moss AJ, Schuger C, Beck CA, Brown MW, Cannom DS, Daubert JP, et al. MADIT-RIT Trial Investigators. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med 2012;367:2275-83.
31. Tsai V, Goldstein MK, Hsia HH, Wang Y, Curtis J, Heidenreich PA. National Cardiovascular Data'sICD Registry. Influence of age on perioperative complications among patients undergoing implantable cardioverter-defibrillators for primary prevention in the United States. Circ Cardiovasc Qual Outcomes 2011;4:549-56.
32. Duray G, Richter S, Manegold J, Israel CW, Gronefeld G, Hohnloser SH. Efficacy and safety of ICD therapy in a population of elderly patients treated with optimal background medication. J Interv Card Electrophysiol 2005;14:169-73.
33. van Rees JB, Borleffs CJ, Thijssen J, de Bie MK, van Erven L, Cannegieter SC, et al. Prophylactic implantable cardioverter-defibrillator treatment in the elderly: therapy, adverse events, and survival gain. Europace 2012;14:66-73.
34. Reynolds MR, Cohen DJ, Kugelmass AD, Brown PP, Becker ER, Culler SD, et al. The frequency and incremental cost of major complications among medicare beneficiaries receiving implantable cardioverter-defibrillators. J Am Coll Cardiol 2006;47: 2493-7.
35. Al-Khatib SM, Greiner MA, Peterson ED, Hernandez AF, Schulman KA, Curtis LH. Patient and implanting physician factors associated with mortality and complications after implantable cardioverter-defibrillator implantation, 2002-2005. Circ Arrhythmia Electrophysiol 2008;1:240-9.
36. Noseworthy PA, Lashevsky I, Dorian P, Greene M, Cvitkovic S, Newman D. Feasibility of implantable cardioverter defibrillator use in elderly patients: a case series of octogenarians. Pacing Clin Electrophysiol 2004;27:373-8.
37. Haines DE, Wang Y, Curtis J. Implantable cardioverter-defibrillator registry risk score models for acute procedural complications or death after implantable cardioverter-defibrillator implantation. Circulation 2011;123:2069-76.
38. Costea A, Rardon DP, Padanilam BJ, Fogel RI, Prystowsky EN. Complications associated with generator replacement in response to device advisories. J Cardiovasc Electrophysiol 2008;19:266-9.
39. Gould PA, Krahn AD. Complications associated with implantable cardioverterdefibrillator replacement in response to device advisories. JAMA 2006;295: 1907-11.
40. Kirkfeldt RE, Johansen JB, Nohr EA, Jørgensen OD, Nielsen JC. Complications after cardiac implantable electronic device implantations: an analysis of a complete, nationwide cohort in Denmark. Eur Heart J 2014;35:1186-94.
41. Lewis EF, Johnson PA, Johnson W, Collins C, Griffin L, Stevenson LW. Preferences for quality of life or survival expressed by patients with heart failure. J Heart Lung Transplant 2001;20:1016-24.
42. Koplan BA, Epstein LM, Albert CM, Stevenson WG. Survival in octogenarians receiving implantable defibrillators. Am Heart J 2006;152:714-9.
43. Pellegrini CN, Lee K, Olgin JE, Turakhia MP, Tseng ZH, Lee R, et al. Impact of advanced age on survival in patients with implantable cardioverter defibrillators. Europace 2008;10:1296-301.
44. Brüllmann S, Dichtl W, Paoli U, Haegeli L, Schmied C, Steffel J, et al. Comparison of benefit and mortality of implantable cardioverter-defibrillator therapy in patients aged = 75 years versus those , 75 years. Am J Cardiol 2012;109:712-7.
45. Shen WK, Hayes DL, Hammill SC, Bailey KR, Ballard DJ, Gersh BJ. Survival and functional independence after implantation of a permanent pacemaker in octogenarians and nonagenarians. A population-based study. Ann Intern Med 1996;125:476-80.
46. Pfisterer M, Buser P, Osswald S, Allemann U, Amann W, Angehrn W, et al. Outcome of elderly patients with chronic symptomatic coronary artery disease with an invasive vs optimized medical treatment strategy: one-year results of the randomized TIME trial. JAMA 2003;289:1117-23.
47. Al-Khatib SM, Hellkamp A, Bardy GH, Hammill S, Hall WJ, Mark DB, et al. Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials. JAMA 2013;309:55-62.
48. Goldenberg I, Vyas AK, Hall WJ, Moss AJ, Wang H, He H, et al. MADIT-II Investigators. Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol 2008;51:288-96.
49. Barsheshet A, Moss AJ, Huang DT, McNitt S, Zareba W, Goldenberg I. Applicability of a risk score for prediction of the long-Term (8-year) benefit of the implantable cardioverter-defibrillator. J Am Coll Cardiol 2012;59:2075-9.
50. Anné W, Theuns DA, Schaer B, Van Belle Y, Szili-Torok T, Smith T, et al. ICDs at higher age and clinical risk factors. Neth Heart J 2014;22:279-85.
51. Parkash R, Stevenson WG, Epstein LM, Maisel WH. Predicting early mortality after implantable defibrillator implantation: a clinical risk score for optimal patient selection. Am Heart J 2006;151:397-403.
52. Chong D, Tan BY, Ho KL, Liew R, Teo WS, Ching CK. Clinical markers of organ dysfunction associated with increased 1-year mortality post-implantable cardioverter defibrillator implantation. Europace 2013;15:508-14.
53. Bilchick KC, Stukenborg GJ, Kamath S, Cheng A. Prediction of mortality in clinical practice for medicare patients undergoing defibrillator implantation for primary prevention of sudden cardiac death. J Am Coll Cardiol 2012;60:1647-55.
54. Kraaier K, Scholten MF, Tijssen JG, Theuns DA, Jordaens LJ, Wilde AA, et al. Early mortality in prophylactic implantable cardioverter-defibrillator recipients: development and validation of a clinical risk score. Europace 2014;16:40-6.
55. Goldenberg I, Moss AJ, McNitt S, Zareba W, Andrews ML, Hall WJ, et al. Multicenter Automatic Defibrillator Implantation Trial-II Investigatorset al. Relations among renal function, risk of sudden cardiac death, and benefit of the implanted cardiac defibrillator in patients with ischemic left ventricular dysfunction. Am J Cardiol 2006;98: 485-90.
56. Hreybe H, Ezzeddine R, Bedi M, Barrington W, Bazaz R, Ganz LI, et al. Renal insufficiency predicts the time to first appropriate defibrillator shock.AmHeart J 2006;151: 852-6.
57. Alba AC, Braga J, Gewarges M, Walter SD, Guyatt GH, Ross HJ. Predictors of mortality in patients with an implantable cardiac defibrillator: a systematic review and meta-Analysis. Can J Cardiol 2013;29:1729-40.
58. Lee DS, Tu JV, Austin PC, Dorian P, Yee R, Chong A, et al. Effect of cardiac and noncardiac conditions on survival after defibrillator implantation. J Am Coll Cardiol 2007; 49:2408-15.
59. Bunch TJ, Day JD, Olshansky B, Stolen KQ, Mullin CM. INTRINSIC RV Study Investigators. Newly detected atrial fibrillation in patientswith an implantable cardioverterdefibrillator is a strong risk marker of increased mortality. Heart Rhythm 2009;6:2-8
60. Chen CY, Stevenson LW, Stewart GC, Seeger JD, Williams L, Jalbert JJ, et al. Impact of baseline heart failure burden on post-implantable cardioverter-defibrillator mortality among medicare beneficiaries. J Am Coll Cardiol 2013;61:2142-50.
61. Rho RW, Patton KK, Poole JE, Cleland JG, Shadman R, Anand I, et al. Important differences in mode of death between men and women with heart failure who would qualify for a primary prevention implantable cardioverter-defibrillator. Circulation 2012;126:2402-7.
62. Peterson PN, Varosy PD, Heidenreich PA, Wang Y, Dewland TA, Curtis JP, et al. Association of single- vs dual-chamber ICDs with mortality, readmissions, and complications among patients receiving an ICD for primary prevention. JAMA 2013;309: 2025-34.
63. Wilkoff BL, Cook JR, Epstein AE, Greene HL, Hallstrom AP, Hsia H, et al. Dual Chamber and VVI Implantable Defibrillator Trial Investigators. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) trial. JAMA 2002;288: 3115-23.
64. Wilkoff BL, Williamson BD, Stern RS, Moore SL, Lu F, Lee SWet al. PREPARE Study Investigators. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study. J Am Coll Cardiol 2008;52:541-50.
65. Gasparini M, Proclemer A, Klersy C, Kloppe A, Lunati M, Ferrer JB, et al. Effect of longdetection interval vs standard-detection interval for implantable cardioverterdefibrillators on antitachycardia pacing and shock delivery: theADVANCE III randomized clinical trial. JAMA 2013;309:1903-11.
66. Tan VH, Wilton SB, Kuriachan V, Sumner GL, Exner DV. Impact of programming strategies aimed at reducing nonessential implantable cardioverter defibrillator therapies on mortality: a systematic review and meta-Analysis. Circ Arrhythm Electrophysiol 2014;7:164-70.
67. Scott PA, Silberbauer J, McDonagh TA, Murgatroyd FD. Impact of prolonged implantable cardioverter-defibrillator arrhythmia detection times on outcome: a meta-Analysis. Heart Rhythm 2014;11:828-35.
68. Looi KL, Gajendragadkar PR, Khan FZ, Elsik M, Begley DA, Fynn SP, et al. Cardiac resynchronisation therapy: pacemaker versus internal cardioverter-defibrillator in patients with impaired left ventricular function. Heart 2014; Apr 1. doi: 10.1136/ heartjnl-2014-305537. [Epub ahead of print
69. Suleiman M, Goldenberg I, Haim M, Schliamser JE, Boulos M, Ilan M, et al. Israeli Working Group on Pacing and Electrophysiology. Clinical characteristics and outcomes of elderly patients treated with an implantable cardioverter-defibrillator or cardiac resynchronization therapy in a real-world setting: data from the Israeli ICD registry. Heart Rhythm 2014;11:435-41.
70. Theuns DA, Schaer BA, Soliman OI, Altmann D, Sticherling C, Geleijnse ML, et al. The prognosis of implantable defibrillator patients treated with cardiac resynchronization therapy: comorbidity burden as predictor of mortality. Europace 2011;13: 62-9.
71. Viana-Tejedor A, Merino JL, Pérez-Silva A, León RC, Reviriego SM, Caraballo ED, et al. Effectiveness of catheter ablation of ventricular tachycardia in elderly patients with structural heart disease. Rev EspCardiol 2010;63:156-60.
72. Inada K, Roberts-Thomson KC, Seiler J, Steven D, Tedrow UB, Koplan BA, et al. Mortality and safety of catheter ablation for antiarrhythmic drug-refractory ventricular tachycardia in elderly patients with coronary artery disease. Heart Rhythm 2010;7: 740-4.
73. Kramer DB, Kennedy KF, Spertus JA, Normand SL, Noseworthy PA, Buxton AE, et al. Mortality risk following replacement implantable cardioverter-defibrillator implantation at end of battery life: results from the NCDRw. Heart Rhythm 2014; 11:216-21.
74. Kini V, Soufi MK, Deo R, Epstein AE, Bala R, Riley M, et al. Appropriateness of primary prevention implantable cardioverter defibrillators at time of generator replacement: are indications still met?. J Am Coll Cardiol 2014;63:2388-94.
75. Alsheikh-Ali AA, Homer M, Maddukuri PV, Kalsmith B, Estes NA 3rd, Link MS. Time-dependence of appropriate implantable defibrillator therapy in patients with ischemic cardiomyopathy. J Cardiovasc Electrophysiol 2008;19:784-9.
76. Schliamser JE, Kadish AH, Subacius H, Shalaby A, Schaechter A, Levine J, et al. DEFINITE Investigators. Significance of follow-up left ventricular ejection fraction measurements in the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation trial (DEFINITE). Heart Rhythm 2013;10:838-46.
77. Erkapic D, Sperzel J, Stiller S, Meltendorf U, Mermi J, Wegscheider K, et al. INSURE Investigators. Long-Term benefit of implantable cardioverter/defibrillator therapy after elective device replacement: results of the INcidence free SUrvival after ICD REplacement (INSURE) trial-A prospective multicentre study. Eur Heart J 2013; 34:130-7.
78. Krahn AD, Lee DS, Birnie D, Healey JS, Crystal E, Dorian P, et al. Ontario ICD Database Investigators. Predictors of short-Term complications after implantable cardioverter-defibrillator replacement: results from the Ontario ICD Database. Circ Arrhythm Electrophysiol 2011;4:136-42.
79. Gould PA, Gula LJ, Champagne J, Healey JS, Cameron D, Simpson C, et al. Outcome of advisory implantable cardioverter-defbrillator replacement: one-year follow-up. Heart Rhythm 2008;5:1675-81.
80. Poole JE, Gleva MJ, Mela T, Chung MK, Uslan DZ, Borge R, et al. REPLACE Registry Investigators. Complication rates associated with pacemaker or implantable cardioverter-defibrillator generator replacements and upgrade procedures: results from the REPLACE registry. Circulation 2010;122:1553-61.
81. KinchWesterdahl A, Sjöblom J, Mattiasson AC, Rosenqvist M, Frykman V. Implantable cardioverter-defibrillator therapy before death: high risk for painful shocks at end of life. Circulation 2014;129:422-9.
82. Naksuk N, Saab A, Li JM, Florea V, Akkaya M, Anand IS, et al. Incidence of appropriate shock in implantable cardioverter-defibrillator patients with improved ejection fraction. J Card Fail 2013;19:426-30.
83. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 2005;353:1471-80.
84. Schackman BR, Gold HT, Stone PW, Neumann PJ. How often do sensitivity analyses for economic parameters change cost-utility analysis conclusions?. Pharmacoeconomics 2004;22:293-300.
85. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, et al. Meta-Analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs implantable defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J 2000;21:2071-8.
86. Poole JE, Johnson GW, Hellkamp AS. Mortality after appropriate and inappropriate shocks in SCD-HeFT (abstract). Heart Rhythm 2006;3:S40.
87. Moss AJ, Greenberg H, Case RB, Zareba W, Hall WJ, Brown MWet al. Long-Term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation 2004;110:3760-5.
88. Zwanziger J, Hall WJ, Dick AW, Zhao H, Mushlin AI, Hahn RM, et al. The cost effectiveness of implantable cardioverter-defibrillators: results from theMulticenter Automatic Defibrillator Implantation Trial (MADIT)-II. J AmColl Cardiol 2006;47:2310-8.
89. O'Brien BJ, Connolly SJ, Goeree R, Blackhouse G, Willan A, Yee R, et al. Cost-effectiveness of the implantable cardioverter-defibrillator: results from the Canadian Implantable Defibrillator Study (CIDS). Circulation 2001;103:1416-21.
90. Noyes K, Corona E, Zwanziger J, Hall WJ, Zhao H, Wang H, et al. Health-related quality of life consequences of implantable cardioverter defibrillators: results from MADIT II. Med Care 2007;45:377-85.
91. Hamilton GA, Carroll DL. The effects of age on quality of life in implantable cardioverter defibrillator recipients. J ClinNurs 2004;13:194-200.
92. Nichol G, Stiell IG, Hebert P, Wells GA, Vandemheen K, Laupacis A. What is the quality of life for survivors of cardiac arrest?. A prospective study. Acad Emerg Med 1999;6:95-102.
93. Greenspon AJ, Patel JD, Lau E, Ochoa JA, Frisch DR, Ho RT, et al. 16-year trends in the infection burden for pacemakers and implantable cardioverter-defibrillators in the United States. J Am CollCardiol 2011;58:1001-6.